St. John's Wort for Depression: Evidence, Risks, and Clinical Guidance
Hypericum perforatum (St. John's Wort) is widely used for mild depression, but evidence is mixed and risks are significant.
Evidence Summary
- Mild–moderate depression: Some meta-analyses show superiority over placebo, comparable to SSRIs (short-term, 4–12 weeks).
- Severe depression: Insufficient evidence; not recommended as monotherapy.
- Long-term (>12 weeks): Limited data; relapse rates unclear.
- Quality concerns: Studies vary in extract standardization (hypericin vs. hyperforin), dose, duration.
Mechanism (Proposed)
Inhibits reuptake of serotonin, dopamine, norepinephrine; modulates GABA/glutamate; anti-inflammatory. Similar to conventional antidepressants but multi-target.
Critical Safety Concerns
| Risk | Details |
|---|---|
| Drug Interactions | Induces CYP3A4 & P-glycoprotein → reduces levels of: oral contraceptives, warfarin, cyclosporine, digoxin, theophylline, HIV protease inhibitors, some chemo, SSRIs (serotonin syndrome risk). 200+ documented interactions. |
| Photosensitivity | Increased sunburn risk; use SPF 30+ |
| Side Effects | GI upset, dizziness, dry mouth, fatigue, sexual dysfunction (similar to SSRIs) |
| Pregnancy/Lactation | Insufficient safety data; avoid |
| Surgery | Discontinue 2–3 weeks prior (bleeding risk, anesthesia interactions) |
